NuCana is no longer a multi-program platform story. It is a cash-backed option on whether a cordycepin analog can reopen checkpoint therapy in melanoma after every standard immunotherapy has already failed. Recruitment in the middle-stage expansion of that combination study is now complete, and the final data package is scheduled for later this year. That is the entire near-term equity argument. Everything else on the Edinburgh balance sheet exists to keep the lights on until that package lands.
The American depositary shares change hands near $1.3. That price capitalizes the equity at about $6 million. Cash at mid-year was roughly $26 million. Enterprise value is deeply negative. That discount is not a rounding error. It is the residue of an abandoned first-generation program, a second asset parked while management hunts for a use, two ratio changes that functioned as reverse splits, and an at-the-market tap that still dribbles stock into a thin book. Cash that funds operations into the end of the decade is real. So is the fact that the company itself says more capital is needed if the melanoma program expands.
The tension is simple. Early combination data in checkpoint-resistant melanoma showed two partial responses and several durable holds, including one conversion to a complete metabolic response, in a still-small treated set. The Food and Drug Administration cleared a United States investigational application in April, which is the first real American regulatory foothold. Whether those signals survive a completed expansion cohort, and whether the agency then offers a workable registrational path rather than a large randomized trial the cash cannot fund, is what the next several months resolve.